Overview

A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

Status:
Not yet recruiting

Trial end date:
2025-04-30

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment. Participants will take treatments and have to use bullets during the study period.

Phase:

Phase 2

Details

Lead Sponsor:

Centre Hospitalier Universitaire de Nice

Treatments:

Deucravacitinib